Form 4: Karyopharm Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Deepika Pakianathan, a director of Karyopharm Therapeutics, acquired 69,000 nonstatutory stock options on May 29, 2024.
Summary
- On May 29, 2024, Deepika Pakianathan, a director of Karyopharm Therapeutics Inc., acquired 69,000 nonstatutory stock options.
- The exercise price of these options is $0.96.
- The options vest 100% on May 29, 2025.
- The options expire on May 28, 2034.
- Following the transaction, Pakianathan directly owns 69,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like directors, buy or sell company stock. This provides transparency to the market regarding insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of transaction: Deepika Pakianathan acquired 69,000 nonstatutory stock options. |
| 05/29/2025 | Vesting date: 100% of the options vest. |
| 05/28/2034 | Expiration date: The options expire. |
| 05/30/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.